Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10271297 | 0.80 | RAB9A (0.63) | RAB9APOLBATMNPC1KMT2A | |
| SCHEMBL13014025 | 0.79 | RAB9A (0.53) | RAB9APOLBATMNPC1KMT2A | |
| SCHEMBL8368023 | 0.76 | ATM (0.72) | RAB9APOLBATMNPC1KMT2A | |
| SCHEMBL17034774 | 0.76 | RAB9A (0.58) | RAB9APOLBATMNPC1KMT2A | |
| SCHEMBL171892 | 0.76 | — | — | |
| SCHEMBL445249 | 0.75 | RAB9A (0.49) | RAB9APOLBATMNPC1KMT2A | |
| SCHEMBL13002465 | 0.75 | GAPDH (0.52) | RAB9APOLBATMNPC1KMT2A | |
| SCHEMBL3009475 | 0.74 | — | — | |
| SCHEMBL28206763 | 0.73 | RAB9A (0.54) | RAB9APOLBATMNPC1KMT2A | |
| SCHEMBL13113182 | 0.73 | RAB9A (0.54) | RAB9APOLBATMNPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668867-B1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | UNIV REGENSBURG (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-11384076-B2 | Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors | UNIVERSITÄT REGENSBURG (DE) | 2022-07-12 | — | — | US | disclosed |
| EP-3668867-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | Universität Regensburg (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-20200190075-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2020-06-18 | — | — | US | disclosed |
| WO-2019034538-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2019-02-21 | — | — | WO | disclosed |
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, PIK3CA, RICTOR | RAB9A 1277/4885POLB 671/4885ATM 391/4885 |
| US-11384076-B2 | Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors | FLT3, CSF3R, ABL1 | RAB9A 4286/4885POLB 3656/4885ATM 192/4885 |
| US-20200190075-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | FLT3, CSF3R, ABL1 | RAB9A 4286/4885POLB 3656/4885ATM 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.